Last reviewed · How we verify
rhIFN beta-1b
rhIFN beta-1b is a Interferon Biologic drug developed by Nuron Biotech Inc.. It is currently in Phase 3 development for Relapsing forms of multiple sclerosis.
rhIFN beta-1b is a recombinant form of interferon beta-1b that modulates the immune system to reduce inflammation in the central nervous system.
rhIFN beta-1b is used to treat Relapsing Remitting Multiple Sclerosis. It is a recombinant human interferon beta-1b, which is a type of protein that has been shown to have therapeutic effects in this condition.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Immunology slight uplift
+1.0pp
Mature endpoint landscape (ACR, DAS28, PASI) makes immunology approvals slightly more predictable.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | rhIFN beta-1b |
|---|---|
| Sponsor | Nuron Biotech Inc. |
| Drug class | Interferon |
| Target | IFN-beta receptor |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
Interferon beta-1b works by binding to the interferon beta receptor, which triggers a signaling cascade that reduces the production of pro-inflammatory cytokines and promotes the production of anti-inflammatory cytokines. This leads to a decrease in inflammation and a reduction in the severity of symptoms associated with multiple sclerosis.
Approved indications
- Relapsing forms of multiple sclerosis
Common side effects
- Flu-like symptoms
- Injection site reactions
- Fatigue
- Headache
- Nausea
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- rhIFN beta-1b CI brief — competitive landscape report
- rhIFN beta-1b updates RSS · CI watch RSS
- Nuron Biotech Inc. portfolio CI
Frequently asked questions about rhIFN beta-1b
What is rhIFN beta-1b?
How does rhIFN beta-1b work?
What is rhIFN beta-1b used for?
Who makes rhIFN beta-1b?
What drug class is rhIFN beta-1b in?
What development phase is rhIFN beta-1b in?
What are the side effects of rhIFN beta-1b?
What does rhIFN beta-1b target?
Related
- Drug class: All Interferon drugs
- Target: All drugs targeting IFN-beta receptor
- Manufacturer: Nuron Biotech Inc. — full pipeline
- Therapeutic area: All drugs in Immunology
- Indication: Drugs for Relapsing forms of multiple sclerosis
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing